HLA-B and infection: The 21 individuals who suffered from XBB.1.16 infection were classified into HLA-B*15 and non-HLA-B*15 groups, ELISA revealed that at M1 and M3 post-BA.5.2 infection, serum from HLA-B*15 individuals manifested dramatically lower concentrations of cross-reactive anti-XBB.1.16 Nab than did serum from non-HLA-B*15 participants (others) (Figure 6E), indicating that HLA-B*15 individuals are more susceptible to XBB.1.16 infection.